Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2021-12-01
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study Assessing Efficacy of an Herbal Blend on Menopausal Symptoms and Quality of Life
NCT04228757
The Effect of Aromatherapy to Women With Vasomotor Complaints on Menopausal Quality of Life and Vasomotor Symptoms
NCT06035380
Dose Finding Evaluation of Kudzu Root Extract in Women With Menopause Symptoms
NCT04552106
Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women
NCT05813067
Symptom Monitoring and Menopausal Symptoms
NCT05603234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The frequency and severity of menopausal symptoms were assessed using an internationally recognized questionnaire menopausal rating scale (MRS). Percentage differences between pre-treatment were compared to post-treatments.
The serum estrogen, progesterone, FSH, and LH levels were measured before and after treatment using a suitable kit for each hormone by Cobas e 411 analyzers (Roche Diagnostics).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group (Ginger)
All the participants were given Zingiber Officinale powder (500 mg) capsules twice daily for twelve weeks.
Zingiber Officinale capsules were purchased from Pure Mountain Botanicals, 1712 Pioneer Ave # 1139 Cheyenne Wyoming 82001 (USA)
Zingiber Officinale powder
Ginger powder
Control group (Placebo)
All the participants were given starch powder (50 mg) capsules twice daily for twelve weeks.
Placebo
Starch powder
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zingiber Officinale powder
Ginger powder
Placebo
Starch powder
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged between 45 and 60 years
Exclusion Criteria
* Patients Having chronic diseases like hypertension, Ischemic heart diseases or Diabetes mellitus
* Patients having coagulopathies
* Patient's having hormone-dependent malignancies
45 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Duhok
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Niroosh Hashim Taha
MSc Student in clinical Pharmacology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Duhok College of Pharmacy
Dihok, Kurdistan Region, Iraq
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24102021-10-36
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.